---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-23-000142"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T05:48:32.865090+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q2 revenue $5.0M (+30% YoY); net loss $14.0M; reaffirms FY2023 guidance

## Summary
- Total revenue $5.0M, up 30% from $3.9M in Q2 2022; net loss $14.0M ($0.33 per share) vs $13.1M ($0.31).
- Recurring revenue $3.6M, up 44% YoY; record consumable revenue; placed two new Growth Direct systems.
- Cash, cash equivalents and investments $113.3M as of June 30, 2023; no debt; cash runway into 2026.
- Reaffirmed FY2023 revenue guidance of at least $22.0M (~30% growth) and at least 15 system placements.
- Appointed Kirk Malloy, Ph.D. as Chair of the Board of Directors.

## SEC filing metadata
- accession: 0001380106-23-000142
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000142/0001380106-23-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000142/rpid-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-23-000142
- JSON: https://secwatch.observer/filing/0001380106-23-000142.json
- Plain text: https://secwatch.observer/filing/0001380106-23-000142.txt

## Key facts
- Earnings Releases
  RAPID MICRO BIOSYSTEMS, INC. reported the second quarter ended June 30, 2023 results: revenue $5.0 million. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $5.0 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: expressly stated in such filing. --- EX-99.1 (EX-99.1) --- Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total revenue guidance of at least $22.0 million, representing growth of approximately 30%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1380106/000138010623000142/0001380106-23-000142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.